Bremelanotide (PT-141): from a tanning peptide's side effect to an approved desire drug

One signal, followed past appetite into desire — the same melanocortin family, surfacing where no one thought to look.

Bremelanotide — better known by its development code PT-141 — is the most unexpected branch of the melanotan family tree. It is the one melanocortin that treats not pigment, appetite, or inflammation, but sexual desire, and it got there entirely by accident.

From a tanning side effect to a drug

In the early trials of Melanotan II — the peptide being pushed as a sunless tan — researchers kept noticing a striking, consistent side effect: spontaneous sexual arousal. Rather than discard it, chemists chased it: they re-worked the MT-II scaffold to strip out most of the pigment activity while keeping the pro-sexual effect, and the result was PT-141.^[1] So where afamelanotide is the tanning side of the melanotan story made into a medicine, bremelanotide is the other side effect made into one.

Desire in the brain, not blood flow downstream

This is what makes it genuinely different from the familiar erection pills. Sildenafil (Viagra) and the other PDE5 inhibitors work peripherally — they improve blood flow to the genitals in response to arousal that isalready present. Bremelanotide works upstream, in the brain: as a melanocortin agonist it activates MC4R (and MC3R) in hypothalamic and limbic circuits that govern sexual motivation itself.^[1] It engages desire and central arousal rather than the plumbing — which is why it can act without direct physical stimulation, and why it is positioned for low desire rather than mechanical dysfunction.

The nasal spray that wasn't

PT-141 was first developed as an intranasal spray for erectile dysfunction. The early data were real: intranasal PT-141 produced statistically significant erectile responses in men with ED, including some who had not responded to sildenafil.^[1][2] But the same melanocortin pharmacology that drives the effect also raises blood pressure, and that signal — together with nausea — ended the intranasal erectile-dysfunction program.^[2] The compound was reformulated as a subcutaneous injection and redirected, and it ultimately reached approval not for men with ED but for women with low desire.

That history matters for two reasons. It is why the approved product is an injection rather than the "nasal spray" still sold informally, and it is why cardiovascular caution runs through everything about this molecule.

What's approved — and what's sold

As Vyleesi, bremelanotide was approved by the FDA in June 2019 for acquired, generalised hypoactive sexual desire disorder (HSDD) inpremenopausal women — the first on-demand treatment for that condition — on the strength of the two phase 3 RECONNECT trials.^[4][5]It is a fixed 1.75 mg subcutaneous autoinjection taken as needed before anticipated activity.^[3]

Everything else is off-label or grey-market. PT-141 is sold online as a "research peptide" — in vials and as compounded nasal sprays — and used by both men and women for libido, none of which is FDA-approved. As with melanotan, the unapproved supply carries the familiar problems: unverified purity and dose, and self-administration of a drug with a real blood-pressure signal. Because the two are so easily mixed up, there's a side-by-side breakdown of PT-141 vs Melanotan.

The 1.75 mg problem — one dose for everyone

Vyleesi is the clearest case study on this site of why dose and delivery — not the molecule alone — decide whether a super-potent peptide is tolerable. The approved product is a single, fixed 1.75 mg subcutaneous dose, identical for every patient, delivered as a sharp bolus by an autoinjector.^[3] There is no titration and no room to adjust: one size for everyone.

For a lifestyle drug taken before sex, the side-effect burden that fixed dose produced is striking. In the phase 3 RECONNECT trials, nausea affected 40% of women versus about 1% on placebo; 13% needed an anti-nausea medication, and 8% quit the trials over nausea alone.^[6] Flushing (about 20%) and headache (about 11%) followed.^[6] The timing is the tell: nausea was worst after the first dose — reported by 21% of patients — then fell to around 3% with later doses, with onset within an hour and lasting about two. That is the profile of an acute reaction to a concentration spike, not a slow-building one.^[3]

And the trial's own pharmacokinetics close the loop: the women who experienced nausea and vomiting had substantially higher blood levels of the drug than the women who did not.^[6] That is the peak-concentration model made explicit — the side effects track how high the drug spikes, exactly as the dose curve predicts, and a fixed high bolus is built to hit that spike in everyone. The pharmacology points to gentler, individualised dosing as the obvious lever on tolerability — something a one-size 1.75 mg product cannot offer. That gap is part of why so much informal "PT-141" use ignores the label dose entirely; but departing from it with grey-market material of unknown purity and strength trades a tolerability problem for a safety one. On why the route itself is not negotiable for a peptide, see why oral peptides mostly don't work.

Side effects — the rest of the melanocortin signature

Beyond nausea, bremelanotide shows the rest of the family resemblance, because it is a non-selective agonist hitting more than its intended receptor. Each dose causes a transient rise in blood pressure with a fall in heart rate — peaking two to four hours out — which is why Vyleesi is contraindicated in uncontrolled hypertension or known cardiovascular disease.^[3] With repeated dosing, focal skin and gum hyperpigmentation can appear — the MC1R pigment effect resurfacing, the same one PT-141 was engineered to minimise but never fully lost.^[3] For why these effects are inseparable from the mechanism, see why melanocortin agonists make you queasy and tan.

The honest bottom line

Bremelanotide is a real, approved, genuinely novel drug — the only one that treats desire through the brain's melanocortin circuitry rather than blood flow. But its approval is narrow (premenopausal women with HSDD), its tolerability is modest (nausea, a blood-pressure rise), and the broad "PT-141 for everyone" sold online is unapproved, of unknown quality, and revives a delivery route its own makers abandoned over safety. The science is real; the grey market around it is not the same thing as the medicine.

Common questions

Is PT-141 FDA approved?+

Yes — as bremelanotide (Vyleesi), but only for acquired, generalised hypoactive sexual desire disorder in premenopausal women, given as a subcutaneous injection. The "PT-141" sold online as a research peptide or compounded nasal spray is not approved.

Does PT-141 work for men?+

Early trials in men with erectile dysfunction — including some who had not responded to Viagra — did show an effect, but the intranasal program was halted over blood-pressure increases and FDA approval for men was never pursued. Any use in men is off-label.

How is PT-141 different from Viagra?+

Viagra and other PDE5 inhibitors work peripherally, improving blood flow in response to arousal that is already present. Bremelanotide works in the brain, activating melanocortin (MC4R) circuits that drive sexual desire itself, so it can act without direct physical stimulation.

What is the difference between PT-141 and Vyleesi?+

They are the same molecule. Vyleesi is the FDA-approved, regulated form — a fixed 1.75 mg autoinjector — whereas "PT-141" usually refers to the unapproved grey-market version, of unknown purity and dose.

What are the side effects of bremelanotide?+

Nausea is the big one — about 40% of women in the approval trials versus ~1% on placebo, and it drove 8% to stop treatment. It was worst after the first dose (about 21% of patients) and eased with later ones, and the women who got sick had higher blood levels of the drug. Each dose also causes a transient rise in blood pressure with a fall in heart rate, so it is contraindicated in uncontrolled hypertension or known cardiovascular disease; repeated dosing can darken skin and gums.

References

1. 1.Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 994:96–102. 2003. link ↗
2. 2.Diamond LE, et al. Double-blind, placebo-controlled evaluation of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 16(1):51–9. 2004. link ↗
3. 3.US FDA / DailyMed. VYLEESI (bremelanotide injection) prescribing information. Label, NDA 210557. 2019. link ↗
4. 4.Kingsberg SA, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials (RECONNECT). Obstet Gynecol. 134(5):899–908. 2019. link ↗
5. 5.Palatin Technologies / AMAG. FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women. Press release. 2019. link ↗
6. 6.Clayton AH, Kingsberg SA, Portman D, et al. Safety profile of bremelanotide across the clinical development program. J Womens Health — pooled adverse-event rates and the link between plasma concentration and nausea. 2022. link ↗